Xia S - Search Results

1

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.

Loomba R, Morgan E, Watts L, Xia S, Hannan LA, Geary RS, Baker BF, Bhanot S. Loomba R, et al. Among authors: xia s. Lancet Gastroenterol Hepatol. 2020 Sep;5(9):829-838. doi: 10.1016/S2468-1253(20)30186-2. Epub 2020 Jun 15. Lancet Gastroenterol Hepatol. 2020. PMID: 32553151 Clinical Trial.

2

Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.

Miner PB Jr, Wedel MK, Xia S, Baker BF. Miner PB Jr, et al. Among authors: xia s. Aliment Pharmacol Ther. 2006 May 15;23(10):1403-13. doi: 10.1111/j.1365-2036.2006.02837.x. Aliment Pharmacol Ther. 2006. PMID: 16669955 Clinical Trial.

3

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.

van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr. van Deventer SJ, et al. Among authors: xia s. Aliment Pharmacol Ther. 2006 May 15;23(10):1415-25. doi: 10.1111/j.1365-2036.2006.02910.x. Aliment Pharmacol Ther. 2006. PMID: 16669956 Clinical Trial.

4

Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.

Miner PB Jr, Geary RS, Matson J, Chuang E, Xia S, Baker BF, Wedel MK. Miner PB Jr, et al. Among authors: xia s. Aliment Pharmacol Ther. 2006 May 15;23(10):1427-34. doi: 10.1111/j.1365-2036.2006.02909.x. Aliment Pharmacol Ther. 2006. PMID: 16669957 Clinical Trial.

5

Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers.

Crooke ST, Baker BF, Kwoh TJ, Cheng W, Schulz DJ, Xia S, Salgado N, Bui HH, Hart CE, Burel SA, Younis HS, Geary RS, Henry SP, Bhanot S. Crooke ST, et al. Among authors: xia s. Mol Ther. 2016 Oct;24(10):1771-1782. doi: 10.1038/mt.2016.136. Epub 2016 Jun 30. Mol Ther. 2016. PMID: 27357629 Free PMC article.

6

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S. Viney NJ, et al. Among authors: xia s. Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21. Lancet. 2016. PMID: 27665230 Clinical Trial.

7

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.

Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, Yamashita M, Rigo F, Hung G, Schneider E, Norris DA, Xia S, Bennett CF, Bishop KM. Finkel RS, et al. Among authors: xia s. Lancet. 2016 Dec 17;388(10063):3017-3026. doi: 10.1016/S0140-6736(16)31408-8. Epub 2016 Dec 7. Lancet. 2016. PMID: 27939059 Clinical Trial.

8

Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)_Rx and IONIS-APO(a)-L_Rx antisense oligonucleotide clinical trials.

Marcovina SM, Viney NJ, Hughes SG, Xia S, Witztum JL, Tsimikas S. Marcovina SM, et al. Among authors: xia s. J Clin Lipidol. 2018 Jan-Feb;12(1):122-129.e2. doi: 10.1016/j.jacl.2017.10.024. Epub 2017 Nov 2. J Clin Lipidol. 2018. PMID: 29174389 Clinical Trial.

9

Integrated Assessment of the Clinical Performance of GalNAc₃-Conjugated 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience.

Crooke ST, Baker BF, Xia S, Yu RZ, Viney NJ, Wang Y, Tsimikas S, Geary RS. Crooke ST, et al. Among authors: xia s. Nucleic Acid Ther. 2019 Feb;29(1):16-32. doi: 10.1089/nat.2018.0753. Epub 2018 Dec 20. Nucleic Acid Ther. 2019. PMID: 30570431 Free PMC article. Clinical Trial.

10

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.

Alexander VJ, Xia S, Hurh E, Hughes SG, O'Dea L, Geary RS, Witztum JL, Tsimikas S. Alexander VJ, et al. Among authors: xia s. Eur Heart J. 2019 Sep 1;40(33):2785-2796. doi: 10.1093/eurheartj/ehz209. Eur Heart J. 2019. PMID: 31329855 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,440 results

Search Page

Filters